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Background: Difficulty in controlling attention can lead to mental fatigue in the healthy population. We identified
one trial reporting a benefit in patients’ attention using a homeopathic formula preparation. One component of the
preparation was potassium phosphate, widely available off the shelf as Kali phos 6x for cognitive problems. The aim
of this exploratory trial was to assess the effectiveness of Kali phos 6x for attention problems associated with mental
fatigue.
Methods: We recruited student and staff volunteers (University of York) with self-reported mental fatigue, excluding
any using homeopathy or prescribed stimulants, or with a diagnosis of chronic fatigue syndrome. In a triple blind,
cross-over, placebo-controlled clinical trial, 86 volunteers were randomized to receive Kali phos 6x or identical
placebo 10 minutes before taking a psychological test of attention (Stroop Colour-Word Test). One week later they
were crossed over and took the other preparation before repeating the test.
Results: We found no evidence of a treatment effect in a comparison of Kali phos 6x with placebo (Kali phos minus
placebo =−1.1 (95% CI −3.0 to 0.9, P = 0.3) Stroop score units, Cohen effect size =−0.17) even when allowing for a
weak period effect with accuracy scores in the second period being higher than those in the first (P = 0.05). We
observed a ceiling effect in the Stroop test which undermined our ability to interpret this result.
Conclusions: Kali phos 6x was not found to be effective in reducing mental fatigue. A ceiling effect in our primary
outcome measure meant that we could not rule out a type II error. Thorough piloting of an adequate outcome
measure could have led to an unequivocal result.
Current Controlled Trials: ISRCTN16521161
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This research was part of a programme evaluating homeop-
athy for attention-deficit/hyperactivity disorder or hyper-
kinetic disorder (ADHD and HKD). We have published a
Cochrane Library review of homeopathy for ADHD and
HKD [1]. The review identified four randomized or quasi-
randomized placebo-controlled trials [2-5] that used behav-
ioural rating scales, three of which also used subscales of
the Conners test [6]. Of the four studies, three used indivi-
dualized ‘classical’ homeopathy and substantial differences
in prescribing methods between trials and conflicting* Correspondence: hugh.macpherson@york.ac.uk
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reproduction in any medium, provided the orresults make this group of studies hard to interpret [7,8]. A
formula ‘complex’ preparation was tested in the fourth
study [4] and appeared to benefit patients’ attention in the
Children’s Checking Task [6]. However, there has been no
independent replication, or further research into the medi-
cation. The clinical effects of its individual components
(homeopathic dilutions of potassium phosphate and selen-
ium), are only known from anecdotal reports in the
homeopathic literature.
Inattention is a problem experienced by many people,
especially those with ADHD in whom it is one of three
core symptoms that can lead to serious psychological,
social and educational/occupational impairment [9]. It
has been proposed that control of attention, impulsestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mental fatigue sets in after extensive use of this mechan-
ism, which may then lead to impaired cognitive function
[10].
Potassium phosphate is traditionally indicated in stand-
ard homeopathic sources for cognitive problems includ-
ing inattention and concentration difficulties [11]. It is
commonly available off the shelf (official nomenclature
Kalium phosphoricum, abbrev. Kali phos) with similar
indications, but there has been no independent research
into its efficacy. As we had encountered difficulties in
gaining ethics approval and support from parents and
care givers for a study with young people diagnosed with
ADHD, we therefore designed an exploratory clinical
trial with an efficient cross-over design to evaluate Kali
phos in treating the specific symptom of mental fatigue
in healthy adult volunteers. In this paper we present the
results of the current trial and some of the difficulties
and problems with the methodology.
Methods
Objectives
To assess the effectiveness of homeopathic potassium
phosphate (Kali phos 6x), an off-the-shelf preparation,
for attention problems associated with mental fatigue in
healthy adults.
Participants
We recruited 86 adult volunteers via online advertise-
ment and internal circulation of emails within the Uni-
versity of York. To be eligible for the study participants
had to self-report difficulties in sustaining attention or be
experiencing mental fatigue. Additionally they had to be
able to communicate in English and consent to avoiding
the use of self prescribed stimulants, such as caffeine and
energy drinks, on the day of each test. We excluded those
who were currently using a homeopathic preparation for
any condition, people who were currently using pre-
scribed stimulant medication such as those used for
ADHD and people diagnosed with chronic fatigue syn-
drome or ME. Those eligible were offered information
leaflets and an explanation of the study by the CI (MED).
All participants gave written consent to participate.
Interventions
The homeopathic preparation was a single dose of 0.6 g of
lactose powder medicated with Kalium phosphoricum 6x
(a decimal dilution equivalent to 1 part in 1 000 000,
potentised by serial agitation) in 90% ethanol/water solu-
tion. The placebo was a single dose of 0.6 g of lactose
powder treated with unmedicated 90% ethanol/water solu-
tion. There was no noticeable difference in taste or ap-
pearance between the two preparations. Both preparations
were supplied by the Helios Pharmacy, London, whocoded the batches A and B so that nobody at the trial
centre was aware which powder was placebo and which
Kali phos. The identity of powders A and B was not
revealed by the pharmacy until after completion of the
analysis. The pharmacy also supplied the manufacturer’s
data sheet for the lactose used in both preparations.
Study design
The study design was a triple-blinded, placebo-
controlled cross-over trial with two arms in which parti-
cipants were randomly allocated to receive either a
homeopathic or placebo preparation in period 1 and vice
versa in the period 2.
In both periods the participants completed the 4-
question mental fatigue sub-scale of the Chalder Fatigue
Questionnaire, giving an integer score between 0 and 4
[12]. They subsequently took a single dose of one of the
randomly allocated preparations. They familiarized
themselves with the software in trial runs of the psycho-
logical test of attention. They then performed the test,
approximately ten minutes after taking either the homeo-
pathic or placebo preparation. Each participant repeated
the procedure at the same time of day, seven days later,
those who received Kali phos in period 1 receiving the
placebo preparation and vice versa. After completing the
period 2 test, participants were asked whether they
thought they had just taken Kali phos or placebo.
Outcomes
A review by Swanson et al. concluded that of three
domains of assessing cognitive deficits, conflict reso-
lution tasks (CRT) were the best at distinguishing chil-
dren in ADHD diagnosed groups from control groups
[13]. Of these CRTs the Stroop Colour-Word Test has
been identified as one of the most sensitive for testing
ADHD-specific deficits [14]. Therefore our primary out-
come measure was accuracy score on the Stroop
Colour-Word Test [15].
The Stroop task involved participants being shown a
colour word (e.g. ‘red’) which was coloured either con-
gruently (e.g. the word ‘red’ was coloured red) or incon-
gruently (e.g. the word ‘red’ was coloured green).
Participants were required to respond to either the word
or the colour of the word by pressing corresponding
keys on the computer keyboard (1 = red, 2 = blue,
3 = green). Participants completed 2 practice blocks each
containing 9 trials (6 incongruent and 3 congruent). In
the first block participants were instructed to respond to
the word and in the second block participants were
instructed to respond to the colour of the word. Feed-
back on performance accuracy was provided during
these practice blocks. Six test blocks, each containing 27
trials (18 incongruent trials and 9 congruent trials) were
then presented. For the first, third and fifth blocks
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ond, fourth and sixth blocks participants responded to
the colour of the word. A recovery period of 30 seconds
in between each test block was included so that the task
was suitable for a linked functional magnetic resonance
imaging investigation (this follow-on project was not
undertaken). The dependent variable was participants’
accuracy score on the incongruent trials (maximum=
108). The test lasted approximately 18 minutes. The
measure was adapted for computer presentation using
EPrimeW software [16] and was used in both periods.
We originally aimed to measure the speed of response
as a secondary outcome, but the software was pro-
grammed with a 3-second delay before the response
screen appeared and therefore this could not be reliably
measured.
Sample size
We wanted to be able to detect a fairly small difference
in the Stroop score and therefore decided to design the
study to detect an effect size of 0.3 standard deviations
with power 0.90 and using a significance level of 0.05.
For a cross-over trial, we would need the standard devi-
ation of differences between repeated measures at a simi-
lar time gap as we proposed for the trial, or the
correlation coefficient between such pairs of observa-
tions. We could find no pre-existing data allowing us to
estimate this correlation, and a pilot study to estimate
this would have been almost as time-consuming to carry
out as the present study. We therefore arbitrarily set the
correlation between the accuracy scores in the first and
second periods to be 0.80, believing this would be a rea-
sonable value for a continuous measurement recorded
with only seven days between measurements. We esti-
mated that 86 volunteers would be required to give the
desired power.
Allocation to treatment order
Allocation was random using our software Clinstat [17] to
allocate 86 participants into equal groups in blocks of ran-
dom sizes 4, 6, 8, or 10. For each participant, the folded
papers containing powders A and B were put by JMB into
clear plastic envelopes and labelled with the participant
number and either “first” or “second”. The completed
packages were passed to MED who administered them to
the participants, all of whom were fully blind to the
allocation.
Statistical analysis
Statistical analysis followed the method of Hills and
Armitage [18] using the description of Altman [19]. We
have followed Senn by not testing the interaction be-
tween treatment and period [20]. As the assumptions of
the two sample t methods used were not well met by thedata, Mann Whitney U tests were used to confirm the
analyses.
Ethical approval
Ethical approval was given by the University of York
Health Sciences Research Governance Committee on




In 2007, 86 participants who were eligible for the study
were randomly allocated to two groups, group A to re-
ceive placebo first and Kali phos second and vice versa
for group B after a one week ‘washout’ period. 84 parti-
cipants completed both periods of the study (Figure 1)
and two participants, both in Group B, were unable to
attend period 2. They were treated as missing completely
at random and not included in the analysis.
Table 1 shows the baseline demographic characteristics
and pre-test data for both groups. The majority of parti-
cipants were female and the majority were students. The
pre-test Chalder Mental Fatigue Score fell significantly
between period 1 and period 2 (P = 0.0004, sign test).
Accuracy scores
Table 2 shows the accuracy scores for Groups A and B
over both periods of the trial. The data are shown graph-
ically in Figure 2. Several things can be seen in these
data. The distribution of score is highly negatively skew,
with a long tail of lower values. There is a clear ceiling
effect, with many participants achieving the maximum
score of 108 in both periods of the trial. There is one ap-
parent outlier in Kali phos period 1. There is little to
suggest a treatment effect, but there may be a period ef-
fect, with period 1 have lower scores than period 2.
The average correlation between the first and second
scores across the two orders was 0.32. This was much
smaller than the 0.80 postulated in the design of the ex-
periment. First we asked whether there was evidence for
a period effect, i.e. are the Stroop accuracy scores in the
first period the same as in the second? For example,
there might be a learning effect, with accuracy increasing
with repetition of the test. If there were no period effect,
we would expect the differences between the treatments
to be the same in the two periods. The period effect, sec-
ond period minus first period, is estimated by the treat-
ment difference for period 2 minus the treatment
difference for period 1. This is 3.9. We can estimate a
95% confidence for this using the two sample t method,
giving 0.0 to 7.8. There is weak evidence of a period ef-
fect, P = 0.05, mean accuracy scores increasing from
period 1 to period 2. Although the two sample t test is
robust to departures from the assumption of a Normal
Eligible participants (n = 86) 
allocated randomly to 1 of 2 
groups
Group A : ‘Placebo first’: 
n  = 43
Period 1: Received 
placebo: n  = 43
Period 2: Received Kali 
phos: n  = 43
Period 2: Received placebo 
: n  = 41: 2 patients did not 
receive period 2 treatment
Group B: ‘Kali phos first’: 
n  = 43
Period 1: Received Kali 
phos: n  = 43
43 patients included in 
main analysis
41 patients included in 
main analysis
Assessed for eligibility (n = 126)
Excluded (n  = 40)
-Withdrew before 
intervention (n = 2)
-Did not attend (n = 5)
-Did not meet Inclusion/ 
exclusion criteria or refused 
to participate (n = 31)
-Other/Unknown (n = 2)
Figure 1 Participants’ flow chart.
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similar, the data clearly do depart from this (Table 2 and
Figure 2). We therefore also tested the period effect
using the Mann Whitney U test. This also provided ra-
ther weak evidence of a period effect, P = 0.05.
We estimated the treatment difference allowing for a
possible period effect from the difference between the
mean differences between periods for those who re-
ceiving placebo first and those who received Kali phos
first. The estimate of the effect, Kali phos minusTable 1 Baseline demographics and pre-test data
Characteristic Placebo first: Kali phos first
n = 43 n= 43
Mean age± SD 33.7 (13.3) 33.44 (13.6)
Female:Male ratio 34:9 31:12
Student:staff ratio 23:20 18:25
Mean (SD) pre-test Mental Fatigue
Score* for period 1
2.8 (1.1) 2.7 (1.0)
Mean (SD) pre-test Mental Fatigue
Score* for period 2
2.3 (1.3) 2.1 (1.2)
* Based on the Chalder Fatigue Questionnaireplacebo, = −1.1 (95% CI −3.0 to 0.9, P = 0.3) Stroop score
units. There is no evidence for a treatment effect. The
non-parametric equivalent is a Mann Whitney U test of
the difference, period 1 minus period 2, between the two
orders. Again there is no evidence for a treatment effect,
P = 0.3. The two analyses give very similar results.
The standard deviation of the first Stroop scores
within treatment groups is 8.6. If we exclude the outlier,
we get 6.5. If we take this as a reasonable estimate of the
baseline standard deviation, we can use it to estimate
the treatment effect in standard deviations. Dividing the
difference in score for Kali phos minus placebo by 6.5
gives −0.17 (95% CI −0.46 to 0.13). Hence the estimated
treatment effect is much smaller than the 0.3 which this
trial was designed to detect and is in the opposite direc-
tion, and 0.3 is not included within the confidence inter-
val and so would not be consistent with the data.
Mental fatigue
The change in the pre-test mental fatigue score from first
to second period was highly significant. Participants were
selected to have self-reported fatigue, but this was not al-
ways reflected in the fatigue score. Two participants had
Table 2 Accuracy scores on the Stroop Colour-Word Test for 86 participants in groups A and B, for periods 1 and 2
Placebo first Kali phos first
Placebo Kali phos Placebo Kali phos Kali phos Placebo Kali phos Placebo
84 108 106 104 50 101 105 107
85 108 106 107 86 99 105 108
88 82 106 107 89 106 106 96
88 89 106 107 91 102 106 108
88 107 106 108 92 100 106 108
91 104 106 108 93 106 106 108
92 107 106 108 93 106 .
93 89 107 100 97 106 107 105
98 89 107 104 99 106 107 106
98 107 107 105 101 103 107 106
101 80 107 107 102 95 107 106
101 90 107 107 102 99 107 107
101 99 107 108 102 101 107 107
103 98 107 108 102 101 107 108
103 106 108 94 102 106 108 107
103 107 108 104 102 108 108 107
104 107 108 106 102 108 108 108
104 108 108 108 103 105 108 108
105 106 108 108 103 108 108 108
105 107 108 108 104 90 108 108
105 108 108 108 105 104 108 108
106 100 105 107
Dean et al. BMC Complementary and Alternative Medicine 2012, 12:167 Page 5 of 7
http://www.biomedcentral.com/1472-6882/12/167a fatigue score = 0, no fatigue, at the first measure-
ment. They were not screened out on the basis of this
score. We asked whether the fall in mean fatigue score
could be a treatment effect? There was no evidence of
this. The mean fatigue scores at the second period
were 2.3 for participants receiving placebo first and 2.1
for participants receiving Kali phos first (P = 0.4, MannFigure 2 Accuracy scores for both groups in both periods.Whitney U test). The corresponding mean falls in fa-
tigue score were 0.5 and 0.6 (P = 0.5).
We then asked whether the change in pre-test mental
fatigue score could explain the period effect. We did this
by analysis of covariance, with treatment, order, and sub-
ject as fixed categorical factors and fatigue score as a
quantitative covariate. The estimated treatment effect,
Kali phos minus placebo, was −1.2 (95% CI −3.1 to 0.8,
P = 0.2), almost identical to the unadjusted analysis. The
estimated period effect, second minus first, was 2.9 (95%
CI 0.8 to 5.0, P = 0.007), smaller than in the unadjusted
analysis but more highly significant. Hence, although
there is evidence that fatigue score did explain some of
the increase in score from the first to the second period,
it did not mask any treatment effect.
Participants’ identification of treatment
Participants were asked at the second visit whether they
could identify which treatment they had just received,
Kali phos or placebo. Of the 84 participants at period 2,
23 guessed Kali phos, 39 guessed placebo, and 22 did
not express an opinion. Of the 62 willing to guess, 29
were correct and 33 were incorrect. There is no evidence
that guesses were other than random (P = 0.7, sign test
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rect). Of those willing to guess, Kali phos was the choice
of 10/30 who actually received Kali phos and 13/32 who
actually received placebo (P = 0.6, chi-squared test).
Potassium content of homeoepathic and placebo
preparations
The manufacturer’s data sheet for the lactose powder
identified numerous trace elements including potassium
(<0.01%). We performed our own chemical analysis
using an atomic absorption spectrophotometer in the
Chemistry Department at the University of York which
showed a potassium content of approximately one part
per million in both Kali phos and placebo preparations.
Discussion
Synopsis of key findings
In a comparison of a homeopathic preparation (Kali
phos 6x) with placebo, in a two period triple blinded
cross over study, we found no evidence of a treatment
effect. There was weak evidence of a period effect where
accuracy scores in the second period were higher than
those in the first across both treatment groups. This
period effect was not explained by a decrease in pre-test
mental fatigue scores from period 1 to period 2. This de-
crease in mental fatigue scores may be attributable to re-
gression towards the mean. Chemical analysis showed
that the (potentized) homeopathic and placebo prepara-
tions both contained approximately 1 part per million of
potassium. Trace elements are not believed to affect the
difference between potentized and unpotentized sub-
stances, as it is the potentization that is considered to
provide the mechanism associated with therapeutic
benefit.
Consideration of findings in respect to the literature
Our Cochrane review of homeopathy for attention def-
icit/hyperactivity disorder [1] found two trials which
measured the specific domain of inattention through
child completed tasks [4,5]. Although the trial of a for-
mula preparation of homeopathic potassium phosphate
and selenium reported some benefit in attention using
the Children’s Checking Task [6], when percentage data
were converted into raw scores and reanalysed there was
no significant difference between homeopathy and pla-
cebo [1]. A pooled estimate of the two trials also indi-
cated no evidence of the effectiveness of homeopathy for
ADHD [1], consistent with the findings of the current
study.
Limitations of study
A clear ceiling effect, as demonstrated in Figure 2, shows
that a large number of accuracy scores were at or close
to 108, the maximum score achievable. It meant thatparticipants who achieved close to the maximum score
in period 1 had little room for improvement in period 2.
This reduced possible difference between mean scores,
but it also reduced the variance of measurements be-
tween participants, so may not have greatly affected the
estimated effect size. The ceiling effect also reduced the
correlation between repeated observations. The original
sample size calculation postulated a correlation of 0.8 be-
tween scores in the first and second periods. The actual
correlation was only 0.3. This must have led to a reduc-
tion in power to detect a treatment difference. The confi-
dence interval for the treatment effect size remained
quite narrow and clearly excluded the difference we set
out to detect, but it remains possible that a more sensi-
tive measurement might produce a different result.
Despite the lack of a positive finding, we support
authors such as Dwan et al [21]. who advocate publish-
ing all studies in order to avoid publication bias in sub-
sequent reviews and meta-analysis. In addition, such
studies such as ours can highlight ways to improve the
research.
The ceiling effect observed was a result of a limitation
in our implementation of the outcome measure used,
the Stroop Colour-Word Test. The test design included
a recovery period of 30 seconds between each block be-
cause the test was intended to be used in a parallel neu-
roimaging study using functional magnetic resonance
imaging. Additionally there was a 3 second gap before
each response could be made. Both these factors meant
that many participants found that the test was not suffi-
ciently challenging. Preliminary assessment of the test
was informally performed on a small number of volun-
teers, however a full pilot study was not. Pilot studies for
cross-over trials are seldom worth conducting as they re-
quire almost as many participants and resources as the
actual trial. As Senn notes [20], cross-over trials are car-
ried out where the condition is not life-threatening and
there is usually no reason why they should not be
repeated with a different design. This is certainly the
case here and if this question were thought worthy of
further research another trial could be carried out using
a more appropriate version of the Stroop test with no
ceiling effect.
Clinical and research implications
Several systematic reviews have outlined the weak evi-
dence for the specific effect of homeopathic remedies
over placebo [22,23]. They go on to highlight the lack of
rigorously conducted randomized controlled trials that
have been published. Such trials have been historically
difficult to perform in the field of complementary and
alternative medicine primarily because of the lack of
funding and because of difficulties in recruiting adequate
numbers of participants [24].
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different methods of diagnosis and prescription [7]. It
has been argued that placebo-controlled trials are in-
appropriate in the evaluation of individualised ‘classical’
homeopathy, which requires therapist-intensive consul-
tations and individualized prescriptions based on each
patient’s symptom picture and unique characteristics
[25]. However formulaic ‘clinical’ homeopathy is widely
available as standardized treatments for predefined con-
ditions or symptoms making it appropriate for rigorous
randomized, placebo-controlled clinical trials, as in the
current study.
Conclusions
Although the current study failed to find any significant
effect of the Kali phos 6x on mental fatigue, this may be
attributable to the methodological flaws in the imple-
mentation of the outcome measure causing a ceiling
effect, so a treatment effect cannot be ruled out. This
study also has implications for further research in com-
plementary and alternative medicine, providing an
example of a resource-efficient cross-over design to
evaluate a treatment for the temporary alleviation of a
stable condition rather than a cure.
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